Navigation Links
Publication in peer-reviewed journal highlights RESPeRATE as effective hypertension treatment
Date:4/22/2009

New York, N.Y.April 22, 2009InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that RESPeRATEthe only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertensionis highlighted as an effective treatment for high blood pressure in the April issue of the Journal of the American Academy of Nurse Practitioners.

The article, written by Elayne DeSimone, ANP, PhD, encourages the entire clinical community, in particular nurse practitioners and physician assistants, to provide individual attention and discuss non-traditional methods when treating patients who suffer from hypertension.

"A patient needs to fully understand his or her individual degree of risk, as well as the consequences of remaining untreated, to feel motivated to take an active part in their healthcare and be compliant with treatment," says DeSimone. "Seven out of 10 patients are not able to achieve their lower blood pressure goals with medication alone, and it is critically important to inform patients of both drug and non-drug treatment options to effectively treat both hypertension and its potential co-morbidities."

In the article, DeSimone highlights the impact of the nurse practitioner as an important source of information and empowerment for the patient. Early detection, monitoring and treatment of hypertension can dramatically reduce the number of hypertensive Americans and have a substantial impact on its associated consequences, both clinically and economically. Promotion of patient awareness and communication, coupled with a blend of drug and non-drug therapies can maximize the effect of a blood pressure treatment regimen.

Diet, exercise and adjunctive treatments are discussed as a way to help patients develop a new routine that fits into their lifestyles and improve treatment compliance. RESPeRATE is highlighted by DeSimone as a treatment that has been proven in multiple clinical studies to produce a significant and lasting decrease in blood pressure, averaging a reduction of 14 points systolic and 8 points diastolic.

"This most recent acknowledgement of RESPeRATE as an effective treatment option for hypertension adds to a growing body of support within the clinical community," says Erez Gavish, president and CEO, InterCure. "Nurse practitioners are vital in providing the best care possible to patients and we hope that these essential caretakers will choose to educate patients about the importance of non-drug therapies such as RESPeRATE."


'/>"/>

Contact: Lisa Mokaba
intercure@schwartz-pr.com
781-684-0770
Schwartz Communications
Source:Eurekalert

Related medicine news :

1. Open access to health research publications
2. Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
3. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
4. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
5. Telemedicine publication expands coverage
6. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
7. Fry Construction Is Featured in Key Industry Publication
8. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
9. Nature publication on pain research
10. Bojan M. Kuure Recognized by Strathmores Whos Who Worldwide Publication
11. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology: